Related Searches : Bivalirudin Trifluoroacetate

Bivalirudin

  • USD 1 - 100 / Gram  
  • 10 Gram/Grams
  • Pharmaceutical Grade
  • 3-5 days afer your payment
  • CAS 128270-60-0
  • Keep in cool dry and dark place
  • Tag:Bivalirudin Trifluoroacetate
  • Supplier - Shenzhen Simeiquan BioChemical Tech Co.ltd
  • China (Mainland)China (Mainland)
  • US$10 Million - US$50 Million
  • Above 1000 People
  • Manufacturer
  • North America,South America,Eastern Europe,Southeast Asia,Africa,Oceania,Mid East,Eastern Asia,Western Europe
  •     
  • skype
  • Ms.Yi
  • 86-027-50755960
Post Date : August 01
Product Details
Company Profile

Item specifics

Pharmaceutical Grade
3-5 days afer your payment
CAS 128270-60-0
Keep in cool dry and dark place
Western Union, Money gram, T/T
Bivalirudin
Auxiliaries and Other Medicinal Chemicals
bella.lee36
C98H138N24O33
99%
China (Mainland),Hubei
White crystalline powder
Discreet Package as your requirement
smile2bella@ycphar.com
128270-60-0
Medicine Grade
YC

Specifications

CAS 128270-60-0 Bivalirudin Trifluoroacetate

98% Injectable Polypeptide Hormones Bivalirudin Trifluoroacetate CAS 128270-60-0 Bivalirudin For Inhibiting Thrombin-mediated Platelet Activation & Aggregation

Bivalirudin Trifluoroacetate

Sequence:D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH

Alias:Angiomax;Bivalirudin;Hirulog

Cas No.: 128270-60-0

Molecular Formula: C98H138N24O33

Molecular Weight: 2180.29

Purity (HPLC): 98.0%min.

Appearance: White Powder

Single Impurity (HPLC): 1.0%max

Amino Acid Composition: ±10% of theoretical

Peptide Content (N%): >80.0%

Water Content (Karl Fischer): <8.0%

TrifluoroAcetate Content(HPIC): >12.0%

MS (ESI): Consistent

Mass Balance: 95.0~105.0%

Grade : Pharmaceutical Grade

Storage: Closed, below 2 ~ 8°C preservation

Usage : This product is mainly used for the prevention of vascular forming interventional therapy in the treatment of unstable angina, ischemic complications before and after.It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation.

Description:

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials

Application:

Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).

Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.

Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Company Related ProductsView the Seller's Products
Bivalirudin Trifluoroacetate

Bivalirudin Trifluoroacetate

Bivalirudin Trifluoroacetate

CAS 128270-60-0 Bivalirudin

98% Injectable Polypeptide Hormones Bivalirudin Trifluoroacetate CAS 128270-60-0 Bivalirudin For Inhibiting Thrombin-mediated Platelet Activation & Aggregation

Bivalirudin Trifluoroacetate

Sequence:D-Phe-Pro-Arg-Pro-Gly-Gly-Gly-Gly-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH

Alias:Angiomax;Bivalirudin;Hirulog

Cas No.: 128270-60-0

Molecular Formula: C98H138N24O33

Molecular Weight: 2180.29

Purity (HPLC): 98.0%min.

Appearance: White Powder

Single Impurity (HPLC): 1.0%max

Amino Acid Composition: ±10% of theoretical

Peptide Content (N%): >80.0%

Water Content (Karl Fischer): <8.0%

TrifluoroAcetate Content(HPIC): >12.0%

MS (ESI): Consistent

Mass Balance: 95.0~105.0%

Grade : Pharmaceutical Grade

Storage: Closed, below 2 ~ 8°C preservation

Usage : This product is mainly used for the prevention of vascular forming interventional therapy in the treatment of unstable angina, ischemic complications before and after.It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation.

Description:

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).

Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.

Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials

Application:

Bivalirudin is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).

Bivalirudin with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

Bivalirudin is indicated for patients with, or at risk of HIT/HITTS undergoing PCI.

Bivalirudin is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin.

Detail more >>
Eptifibatide

Eptifibatide

Eptifibatide

CAS 148031-34-9 Eptifibatide

CAS NO.: 148031-34-9

Assay: 98.5% min.

Grade: Pharmaceutical Grade

Storage: Preserve in tight, light resistant containers, store in a refrigerator(2-8° C)

Molecular Formula: C35H49N11O9S2

Molecular weight: 831.96

Appearance: White powder

Sequence: Mpr-Harg-Gly-Asp-Trp-Pro-Cys)-NH2

Application:

1. Eptifibatide is used to reduce the risk of acute cardiac ischemic events (death and/or myocardial infarction) in patients with unstable angina or non-ST-segment-elevation (e. G., non-Q-wave) myocardial infarction (i. E., non-ST-segment elevation acute coronary syndromes) both in patients who are to receive non surgery (conservative) medical treatment and those undergoing percutaneous coronary intervention (PCI).

2. Treat the adults and the children above6 years old chronic humanity flaw virus(HIV)infects. Chronic humanity flaw virus(HIV)infects.

Detail more >>
The informations displayed above are provided by the seller. The authenticity, accuracy and legality of the content are borne by the seller. Please realize that the risks in Internet transactions are objective.
Talk with SupplierX
Jeana Yi:
Can I help you?
Contact Supplier

Selected(1/4)Contact or Compare